Skip to Main content Skip to Navigation
Journal articles

Effects of dexamethasone on immune dysfunction and ventilator-associated pneumonia in COVID-19 acute respiratory distress syndrome: an observational study

Abstract : Dexamethasone improves survival of patients with COVID-19 acute respiratory distress syndrome, but might shorten the delay between the start of invasive mechanical ventilation and the occurrence of ventilator-associated pneumonia, suggesting possible worsening of COVID-19-induced immune dysfunction with this treatment. In a prospective observational study, we found that mechanically ventilated patients with COVID-19 treated with dexamethasone presented earlier ventilator-associated pneumonia, had significantly lower monocyte Human Leukocyte Antigen-DR expression and number of circulating CD4 + cells after ICU admission, than those not treated with corticoids.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03753365
Contributor : laboratoire CarMeN Connect in order to contact the contributor
Submitted on : Thursday, August 18, 2022 - 11:16:41 AM
Last modification on : Saturday, September 24, 2022 - 3:10:05 PM

File

s40560-021-00580-6.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

M. Cour, M. Simon, L. Argaud, G. Monneret, F. Venet. Effects of dexamethasone on immune dysfunction and ventilator-associated pneumonia in COVID-19 acute respiratory distress syndrome: an observational study. Journal of Intensive Care, BioMed Central, 2021, 9 (1), pp.64. ⟨10.1186/s40560-021-00580-6⟩. ⟨inserm-03753365⟩

Share

Metrics

Record views

613

Files downloads

4103